CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

A 14-month randomized trial in older African American adults with obesity found that adopting a Mediterranean diet, with or ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...

Obesity is a significant risk factor for osteoarthritis, particularly in weight-bearing joints, like the knees. A doctor shares what women need to know.

Actor Ram Kapoor has been in the news for his dramatic weight loss. The actor said that he did not do it for the roles but ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

The Saudi Arabia weight loss market reached USD 1.6 billion in 2024 and is projected to climb to USD 2.7 billion by 2033, reflecting a compound annual growth rate (CAGR) of 5.68% from 2025 to 2033.

Eli Lilly said on Thursday that India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with Novo ...

This summary covers recent developments in health from the death tied to a cyberattack on Synnovis services in the UK, the Eli Lilly and Novo Nordisk rivalry in the weight-loss drug market in India, ...

Women with diabetes who were overweight or had obesity lost more weight and had greater odds of diabetes remission when ...